Pioneering medical screening test company Premaitha Health has struck a £5m investment deal with one of the world’s largest scientific groups.
The Manchester-based firm, which has developed a pioneering non-invasive prenatal screening test called IONA, said its deal with Thermo Fisher Scientific will allow it to roll-out the product to more clinical laboratories across Europe and also boost further product development.
Thermo Fisher is the world leader in serving science, with revenues of $17bn and approximately 50,000 employees in 50 countries.
Dr Stephen Little, chief executive of Premaitha, said: “We have strengthened our relationship with Thermo Fisher as an investor in our business. This investment will enable us to expand our global reach, support our marketing and clinical and technical capabilities. It will also provide future product development opportunities in the rapidly growing non-invasive prenatal testing market.”
See article in full at BusinessDesk.com